文献速递儿童青少年精神

儿童期ADHD哌甲酯疗效的药物遗传学预测因素

Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD.
PubMed 文献 · Mol Psychiatry · 2017-12-12

该元分析纳入36项研究共3647名儿童,探讨DNA变异与哌甲酯疗效的关联。汇总数据显示ADRA2A rs1800544、COMT rs4680、SLC6A2 rs5569和rs28386840、DRD4 VNTR 4及SLC6A3 VNTR 10与疗效显著相关;LPHN3两个SNP及DRD4 VNTR 7无显著关联。SLC6A3研究存在漏斗图不对称,主要归因于小样本效应。

要点

  • ADRA2A rs1800544、COMT rs4680、SLC6A2 rs5569和rs28386840与哌甲酯疗效显著相关。
  • DRD4 VNTR 4与疗效正相关,SLC6A3 VNTR 10与疗效负相关。
  • LPHN3 rs1947274、rs5661665及DRD4 VNTR 7与疗效无显著关联。

核心结论

  • 多个儿茶酚胺系统相关基因变异与儿童期ADHD哌甲酯疗效存在显著关联,支持药物遗传学指导的个体化治疗。

研究设计与样本

  • 元分析纳入36项研究,共3647名儿童,评估DNA变异与哌甲酯治疗效果的关联。

主要发现

  • ADRA2A rs1800544与哌甲酯疗效显著相关(OR=1.69,95%CI 1.12-2.55)。
  • COMT rs4680与哌甲酯疗效显著相关(OR=1.40,95%CI 1.04-1.87)。
  • SLC6A2 rs5569与哌甲酯疗效显著相关(OR=1.73,95%CI 1.26-2.37)。
  • SLC6A2 rs28386840与哌甲酯疗效显著相关(OR=2.93,95%CI 1.76-4.90)。
  • DRD4 VNTR 4与哌甲酯疗效显著相关(OR=1.66,95%CI 1.16-2.37),SLC6A3 VNTR 10与疗效显著负相关(OR=0.74,95%CI 0.60-0.90)。

关键数值与推荐

  • LPHN3 rs1947274与哌甲酯疗效无显著关联(OR=0.95,95%CI 0.71-1.26)。
  • LPHN3 rs5661665与哌甲酯疗效无显著关联(OR=1.07,95%CI 0.84-1.37)。
  • DRD4 VNTR 7与哌甲酯疗效无显著关联(OR=0.68,95%CI 0.47-1.00)。
  • SLC6A3研究存在漏斗图不对称,主要归因于小样本效应,采用Egger回归检验及Duval和Tweedie剪补法评估和校正发表偏倚。

临床怎么用

  • 临床可参考ADRA2A、COMT、SLC6A2、DRD4及SLC6A3特定变异评估哌甲酯疗效预期,推动个体化用药。

局限性

  • SLC6A3相关研究存在小样本效应导致的漏斗图不对称,可能影响结果稳健性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stimulant medication has long been effective in treating attention-deficit/hyperactivity disorder (ADHD) and is currently the first-line pharmacological treatment for children. Both methylphenidate and amphetamine modulate extracellular catecholamine levels through interaction with dopaminergic, adrenergic and serotonergic system components; it is therefore likely that catecholaminergic molecular components influence the effects of ADHD treatment. Using meta-analysis, we sought to identify predictors of pharmacotherapy to further the clinical implementation of personalized medicine. We identified 36 studies (3647 children) linking the effectiveness of methylphenidate treatment with DNA variants. Pooled-data revealed a statistically significant association between single nucleotide polymorphisms (SNPs) rs1800544 ADRA2A (odds ratio: 1.69; confidence interval: 1.12-2.55), rs4680 COMT (odds ratio (OR): 1.40; confidence interval: 1.04-1.87), rs5569 SLC6A2 (odds ratio: 1.73; confidence interval: 1.26-2.37) and rs28386840 SLC6A2 (odds ratio: 2.93; confidence interval: 1.76-4.90), and, repeat variants variable number tandem repeat (VNTR) 4 DRD4 (odds ratio: 1.66; confidence interval: 1.16-2.37) and VNTR 10 SLC6A3 (odds ratio: 0.74; confidence interval: 0.60-0.90), whereas the following variants were not statistically significant: rs1947274 LPHN3 (odds ratio: 0.95; confidence interval: 0.71-1.26), rs5661665 LPHN3 (odds ratio: 1.07; confidence interval: 0.84-1.37) and VNTR 7 DRD4 (odds ratio: 0.68; confidence interval: 0.47-1.00). Funnel plot asymmetry among SLC6A3 studies was identified and attributed largely to small study effects. Egger's regression test and Duval and Tweedie's 'trim and fill' were used to examine and correct for publication bias. These findings have major implications for advancing our therapeutic approach to childhood ADHD treatment.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Myer NM, Boland JR, Faraone SV, et al. Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry. 2017. PMID: 29230023. doi:10.1038/mp.2017.234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。